Ursoft

Quick links to important sections

Ursoft

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursoft

Quick Facts

Property Description
Active ingredient Ursodeoxycholic Acid (UDCA)
Form Capsule, Tablet, or Oral Suspension
Pharmacological Class Bile Acid Preparation, Hepatoprotective
Common Use Management of hepatobiliary and cholestatic conditions
Origin Semi-synthetic secondary bile acid

What Type of Medicine is Ursoft (Ursodeoxycholic Acid)?

Ursoft is a prescription bile acid preparation that contains the single active substance, Ursodeoxycholic Acid (UDCA). Pharmacologically, it is classified as a hepatoprotective agent and a cholagogue, used to influence the flow and chemical structure of bile. The core ingredient, UDCA, is a secondary bile acid that occurs naturally as a minor component within the human bile acid pool. For therapeutic use, it is manufactured in a highly purified, semi-synthetic form.

UDCA's key differentiating feature is its high hydrophilicity (water-solubility). This structural characteristic is clinically recognized as supporting its low toxicity profile compared to other naturally occurring, more hydrophobic bile acids. Ursoft is positioned as a monocomponent oral product used in situations where bile composition or flow requires therapeutic modification.

Forms and Purpose: Delivery and General Benefit

Ursoft is designed for oral administration and is distinguished by its availability in several distinct forms: capsules, film-coated tablets, and an oral liquid preparation (suspension). This range of pharmaceutical presentations is intended to support consistent treatment, accommodating different patient needs, such as those who may require the liquid suspension for easier swallowing.

The general purpose of this medicine is rooted in the normalization of the biliary environment and the provision of cytoprotection (cell protection). Ursoft functions by integrating into the existing bile acid pool to modify the composition of bile, primarily by reducing the amount of cholesterol secreted by the liver, and by providing a protective effect to liver and bile duct cells. This foundational action supports the overall health and function of the liver and associated biliary system.

What side effects are possible with Ursoft?

Possible Side Effects and Safety Information

Regulatory documents classify the possible side effects of Ursoft (Ursodeoxycholic Acid) based on their frequency and the system-organ class affected. The most frequently documented adverse reactions primarily involve the digestive system.

Frequency Classification (Regulatory Standard) Common Adverse Reactions (1 in 100 to 1 in 10)
Common Pasty stools or diarrhoea

The official safety profile notes several important adverse reactions that have been observed, although at a Very Rare frequency (less than 1 in 10,000 users). These serious reactions are typically related to the hepatobiliary system and include the decompensation of hepatic cirrhosis, particularly in patients with advanced Primary Biliary Cholangitis (PBC). Additionally, the calcification of non-calcified gallstones may occur in very rare instances, making them unsuitable for further bile acid dissolution therapy.

Initial treatment with Ursoft requires specific safety monitoring. Regulatory labeling mandates that liver function tests (such as AST, ALT, and gamma-GT) should be monitored monthly for the first three months and then every six months thereafter to allow for the early detection of any changes in hepatic function.

Specific restrictions define when the medicine should not be used (contraindications). These include patients with acute inflammation of the gallbladder or biliary tract, complete obstruction of the biliary tract, frequent episodes of biliary colic, or the presence of radio-opaque calcified gallstones.

Overdose and Emergency Response

Ursoft Overdose and When to Seek Help

The official regulatory profile for Ursodeoxycholic Acid (Ursoft) describes a low likelihood of severe systemic toxicity in overdose situations. According to major regulatory documents, accidental or intentional human overdosage has been largely unreported, and severe, life-threatening outcomes are classified as unlikely to occur. This finding is attributed to the drug's self-limiting nature, where high doses result in reduced absorption and increased excretion through the feces.

The most likely clinical manifestation of a severe overdosage is diarrhea. Immediate medical attention must be sought upon suspicion of an overdose or at the onset of any serious adverse reaction. If persistent diarrhea develops, official regulatory guidance explicitly states that the therapy should be discontinued.

Management of an overdose is defined as symptomatic and supportive, as no specific antidote is known. Required procedural steps include the mandatory monitoring of liver function tests during the acute phase. Furthermore, regulatory context mentions the possible use of ion-exchange resins to bind excess bile acids in the intestine. The overall structure of the official advice directs attention toward managing symptomatic effects and ensuring hepatic stability.

Therapeutic Uses of Ursoft

Ursoft is a specialized bile acid preparation commonly used in conditions presenting with systemic or localized discomfort linked to the liver and biliary system. The medication is typically applied across three main therapeutic domains.


Management of Chronic Cholestatic Liver Disease

Ursoft is relevant in the long-term management of chronic conditions, most notably Primary Biliary Cholangitis (PBC). This therapy is applied to address symptom clusters related to systemic imbalance, such as debilitating pruritus (severe itching), and may assist with managing elevated liver enzyme levels. The key patient benefit supports efforts to manage the condition's progression, contributing to the maintenance of stable liver function and overall long-term comfort.

The common therapeutic applications are relevant for the management of Primary Biliary Cholangitis (PBC), may assist with the dissolution of cholesterol gallstones, and supports efforts in the prevention of stones in high-risk scenarios like rapid weight loss or post-bariatric surgery.

Dissolution and Prevention of Cholesterol Gallstones

The medication is considered relevant in the management of gallstone disease, and may assist with the dissolution of small, non-calcified cholesterol gallstones. It is also frequently applied in a preventative role for patients undergoing rapid weight loss, a scenario known to increase the risk of stone formation. This use offers symptomatic relief and may help with managing the discomfort associated with episodes like biliary colic.

“Ursoft supports efforts to manage the condition’s progression, contributing to the maintenance of stable liver function and overall long-term comfort.”

Supportive Care in Specialized Biliary Scenarios

Ursoft is also relevant in specific clinical scenarios requiring supportive symptom management for the liver and biliary system. This includes the management of Intrahepatic Cholestasis of Pregnancy (ICP), where it is used to help ease the mother's intense itching, and in certain liver complications associated with Cystic Fibrosis. This supportive use helps manage heightened symptomatic phases and provides support that contributes to easing the overall symptom load and assists with maintaining functional stability.


Quick Fact: Supports Symptom Management

Regulatory References

  1. NIH MedlinePlus overview of Ursodiol

Eligibility and Restrictions for Use

Who Can and Cannot Use Ursoft?

Ursoft (Ursodeoxycholic Acid) is officially indicated for adults with Primary Biliary Cholangitis (PBC) or those requiring the dissolution of radiolucent, non-calcified cholesterol gallstones. Use in the general pediatric population for these indications is not established due to limited data, though specific eligibility exists for children with Cystic Fibrosis-associated hepatobiliary disorders.


Contraindications and Restrictions

Absolute contraindications prohibit the use of Ursoft in patients with known hypersensitivity to the drug or in the presence of complete biliary obstruction or acute inflammation of the gallbladder or biliary tract. For gallstone dissolution, the medicine must also not be used if the gallstones are calcified or if the gallbladder's contractility is impaired.

Use is restricted in other specific groups. For the treatment of PBC, patients with decompensated cirrhosis are generally excluded. Use is not recommended during pregnancy or requires caution during lactation, as adequate human safety studies are lacking. Patients with pre-existing liver disease require mandatory and close regulatory monitoring of liver function throughout therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ursodeoxycholic Acid (Ursoft) has officially documented interaction patterns that are defined by regulatory authorities based on their impact on Ursoft’s absorption or its clinical efficacy.

Interactions Affecting Absorption

Substances that bind or sequester bile acids in the gastrointestinal tract interfere with Ursoft’s action by reducing its absorption. This group includes Bile Acid Sequestering Agents (e.g., Cholestyramine, Colestipol), Aluminum-based Antacids, and Charcoal.

The regulatory constraint for co-administration is a mandatory separation of timing: these preparations must be taken at least 2 hours before or after Ursodeoxycholic Acid to mitigate the reduction in exposure.

Interactions Counteracting Efficacy

Certain medicinal products are documented to promote hepatic cholesterol secretion, which directly counteracts Ursoft's effect on bile composition. Products containing Estrogens, Oral Contraceptives, and the lipid-lowering drug Clofibrate fall into this category, resulting in a reduction in therapeutic effectiveness.

Altered Exposure of Co-administered Drugs

Regulatory documents also state that Ursoft can modify the exposure of other medicines. This includes an increase in the intestinal absorption of Ciclosporin, which may raise its plasma concentration. Conversely, Ursoft can reduce the therapeutic effect or plasma exposure of drugs such as Nitrendipine, Dapsone, and Ciprofloxacin.

Mechanism of Action

Ursoft (Ursodeoxycholic Acid or UDCA) exerts its action through complementary pharmacodynamic mechanisms that restructure bile acid composition and modulate stability within the hepatobiliary system.

Cellular Cytoprotection and Bile Acid Pool Modulation

This domain addresses the drug's role in stabilizing the cellular environment. It works by displacing accumulated toxic hydrophobic bile acids and stabilizing hepatocellular and cholangiocyte membranes. By targeting the Mitochondrial Permeability Transition Pore, UDCA actively modulates the cascade of events that leads to cell death (apoptosis), influencing the mechanisms of cellular degradation in the liver and bile duct lining.

Transporter Stimulation and Enhanced Bile Flow

This mechanism is focused on increasing the capacity of the hepatobiliary transport system. UDCA upregulates key hepatic transporters, such as BSEP and MRP2, increasing the liver's capacity to export substances into the bile. This generates a higher volume, bicarbonate-rich choleretic flow that facilitates the accelerated movement and clearance of compounds from the biliary system.

Biliary Chemistry and Cholesterol Solubilization

This mechanism alters the physical chemistry of bile to decrease the saturation of cholesterol. UDCA reduces the secretion of cholesterol from the liver and promotes the formation of highly soluble mixed micelles within the bile fluid. This maintains a state of low cholesterol saturation, promoting the stability of cholesterol in its soluble phase.

Dosage and Administration Information

The instructions for using Ursoft (ursodiol) define a specific oral dosing regimen that is based on the patient's body weight and must be administered with food.

Dosing and Administration

The recommended adult daily dosage is typically calculated based on body weight, falling in the range of 13–15 mg/kg/day. This total daily dose must be divided and administered in two to four servings throughout the day. The dosing schedule is subject to adjustment by a healthcare provider based on the patient's individual needs.

Procedural Step Instruction
Route & Timing Taken orally with water and must be administered with food.
Tablet Preparation The 500 mg scored tablet can be broken in half to achieve the prescribed dose. Do not crush or chew.
Missed Dose Take the missed dose as soon as you recall it. If it is almost time for the next dose, skip the missed dose and continue the regular schedule. Do not take a double dose to catch up.

Patients must swallow the tablet or half-segment whole and ensure any unused half-segments are stored separately from whole tablets to maintain proper quality and taste. Liver function tests are typically monitored periodically to allow for the early detection of any change in hepatic function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ursoft

Evidence for Use in Primary Biliary Cholangitis (PBC)

The research exploring outcomes for Primary Biliary Cholangitis (PBC) includes many randomized controlled trials (RCTs) and long-term observational studies. Researchers examined outcomes related to patient survival, the need for liver transplantation, and measured changes in biochemical markers, such as liver enzyme levels. Studies exploring outcomes in patients treated with Ursoft have reported patterns of liver enzyme levels shifting toward or reaching predefined normal criteria in many patients during the initial years of being studied. Long-term observational research also described patterns related to longer time periods without critical events being observed in specific cohorts.

Evidence for Gallstone Dissolution and Prevention

Ursoft was studied for its potential role in managing cholesterol gallstone disease. The primary goal of this research was to track the rate at which existing, non-calcified cholesterol stones achieved complete dissolution in the gallbladder. Trials observed patterns of complete gallstone dissolution in a subset of selected patients, with success often dependent on the initial size and composition of the stones. However, studies also described a high rate of recurrence (stones reforming) after the observation period ended, highlighting the need for long-term follow-up data.

Evidence for Use in Cholestasis of Pregnancy and Cystic Fibrosis-Related Liver Disease

Research for Intrahepatic Cholestasis of Pregnancy (ICP) involved randomized controlled trials tracking maternal symptoms (pruritus) and serum bile acid concentrations. Studies reported that women receiving the compound experienced lower measurements of bile acid levels and reported differences in the severity of itching. However, findings regarding the impact on fetal outcomes, such as stillbirth, were mixed or inconsistent across some large RCTs, and confidence in these outcomes is limited.

For Cystic Fibrosis-Associated Liver Disease (CFLD), research is characterized by small, short-term trials in children and adolescents. These studies tracked shifts in liver enzyme levels. There is a lack of data from robust trials to describe a sustained prevention of severe disease progression over the long term.

What Remains Uncertain About Ursoft Research

The available research provides context but also highlights several areas where data is insufficient. For ICP, conflicting data remains regarding a definitive impact on the risk of severe fetal outcomes. For both gallstone dissolution and CFLD, the data for long-term outcomes are insufficient to describe a sustained prevention of severe disease or recurrence. Generally, findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Randomised controlled trial of ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy
  2. Intrahepatic Cholestasis of Pregnancy – Diagnosis and Management: SOMANZ Consensus Statement

Frequently Asked Questions (FAQ)

Common questions about Ursoft (FAQ)


Q: What is the difference between Ursoft and other drugs for the same condition?

Regulatory documents describe the active ingredient, ursodeoxycholic acid, as a highly hydrophilic (water-soluble) secondary bile acid. This chemical characteristic allows the ingredient to integrate into the body's bile acid pool. Regulatory documents describe this structural difference in the context of its intended effect on the bile acid pool.


Q: Is it normal to feel tired when first starting Ursoft?

The official safety profile for the medication documents fatigue and unusual tiredness or weakness among the reported side effects. While the frequency can vary, this information is included in the list of possible adverse reactions that have been observed with Ursoft use.


Q: What should I do if I miss a dose of Ursoft?

The official procedure for a recalled dose is described in patient information. Official information outlines the procedure for skipping a dose when the next scheduled administration is near. The procedure also describes not taking a double dose to compensate for the missed one.


Q: Can Ursoft be crushed or split?

The scored tablet form is designed so it can be broken in half, if needed, to meet a specific prescribed dose. Official directions describe the tablet or half-segment as being intended to be swallowed whole with water. Regulatory information specifically states that the tablets should not be crushed or chewed.


Q: Is Ursoft safe to use while breastfeeding is described in the official documents?

Regulatory documents state that it is unknown if the active ingredient is excreted into human breast milk. Due to the lack of sufficient human studies on this topic, official documents describe the need for caution during lactation.


Q: Does Ursoft contain lactose or gluten?

The official product information lists all inactive ingredients (excipients) used in the formulation. While the exact excipient list may differ slightly between forms, manufacturers adhere to regulatory guidelines regarding common allergens. Patients with dietary restrictions can review the full list of inactive ingredients for their specific formulation.


Q: What is the chemical name for Ursoft?

Ursoft's active ingredient is Ursodeoxycholic Acid, and its full chemical name as described in regulatory documents is 3alpha,7beta- Dihydroxy-5beta- cholan-24- oic acid.


Q: How quickly should I expect to notice an effect from Ursoft?

Research studies indicate that the goal of treatment is the modification of bile composition, which is a gradual process. Improvement in measured biochemical parameters (like certain liver enzyme levels) is typically observed within 3 to 6 months after treatment initiation.


Q: Do I have to take Ursoft forever?

The required duration of therapy depends entirely on the condition being treated. For the indication of Primary Biliary Cholangitis (PBC), the treatment is generally described in official recommendations as long-term and indefinite to help slow the progression of the disease.


Q: Can Ursoft cause weight changes?

The official safety profile documents that unusual weight gain or loss and rapid weight gain have been reported as side effects. These reports are generally classified in the incidence categories of uncommon or unknown frequency.


Q: What happens if I stop taking Ursoft suddenly?

Official patient guidance emphasizes the importance of continuing the prescribed regimen. The medication is not intended to be stopped without consultation from a healthcare professional who manages the condition.


Q: What is the typical duration of treatment with Ursoft?

The length of treatment varies by condition. For cholesterol gallstone dissolution, therapy may be required for several months, with safety data for use beyond two years being limited. For Primary Biliary Cholangitis (PBC), the treatment is typically administered on a long-term, continuous basis.


Q: Will taking Ursoft affect my driving ability?

The official safety information notes that side effects such as dizziness and headache are commonly reported with this medication. General caution in patient guides describes being careful when operating machinery or driving until one understands how the medicine affects their personal physical state.


Q: Is it common for Ursoft to cause stomach upset?

Yes, regulatory documents classify gastrointestinal issues as common adverse reactions. Side effects such as diarrhea and pasty stools are frequently reported. Other types of stomach upset, including abdominal pain, nausea, and vomiting, are also commonly documented in the safety profile.


Q: Does Ursoft need to be taken at the same time every day?

While the total daily dose is typically divided and taken multiple times, official patient guides suggest taking the medication at the same time each day to maintain treatment adherence. This consistent timing helps ensure stable concentrations of the active ingredient in the body throughout the treatment period.


Q: What is the safety profile of Ursoft for long-term use?

The long-term safety profile is addressed by regulatory bodies, which mandate regular liver function monitoring throughout the course of therapy. The profile also highlights the need for continuous monitoring, noting rare but serious risks such as the potential for decompensation of hepatic cirrhosis in patients with advanced PBC.

How should Ursoft be stored and disposed of?

How to Store and Dispose of Ursoft?

The storage and disposal of Ursoft (ursodeoxycholic acid) must strictly adhere to the conditions mandated by regulatory labeling to maintain product stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep in a tight, light-resistant container and protect from moisture and excessive heat. Do not freeze.
Child Safety Must be kept out of the sight and reach of children.
Scored Tablets Half-tablets, if scored, should be used within 28 days and stored separately from whole tablets.

Disposal

Unused or expired Ursoft must be disposed of using an authorized drug take-back program. The medicine must not be flushed down a toilet or sink to protect the wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ursoft found in:

A-Z Index: